Immunotherapy in Cancer Treatment: Current and Future Directions

Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood. 1992; 80(4):863– 878. [PubMed: 1498329]

Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005; 46(Suppl 1):S115–S127.

Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010; 10(5):317–327

Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010; 9(10):767–774

Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828–36

Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, et al. Immune checkpoints inhibitors: recent data from ASCO’s meeting 2017 and perspectives. Bull Cancer. 2018;105(7–8):686–95

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10

Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–32

Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 2017;8:22

Yamazaki T, Kirchmair A, Sato A, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol 2020;21:1160– 71

Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease TREX1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 2017;8: 15618

Lejeune P, Cruciani V, Berg-Larsen A, et al. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti- PD-L1 therapy. J Immunother Cancer 2021;9:e002387

Pressman D, Day ED, Blau M. The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res. 1957;17:845–850

Bale WF, Spar IL, Goodland RL. Experimental radiation therapy of tumors with I-131-carrying antibodies to fibrin. Cancer Res. 1960;20:1488–1494

Goldenberg DM. Imaging and therapy of cancer with radiolabeled monoclonal antibodies. Prog Clin Biol Res. 1989;288:413–427.

Larson SM, Carrasquillo JA, Reynolds JC. Radioimmunodetection and radioimmunotherapy. Cancer Invest. 1984;2:363–381

Kim EE, Deland FH, Casper S, Corgan RL, Primus FJ, Goldenberg DM. Radioimmunodetection of colorectal cancer. Cancer. 1980;45:1243–1247

Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature. 1985;316:265–268

Goodwin DA, Meares CF, McTigue M, David GS. Monoclonal antibody hapten adiopharmaceutical delivery. Nucl Med Commun. 1986;7:569–580

Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med. 1988;29:226–234.

Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650–6655

Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294–1302.

Pimm MV, Fells HF, Perkins AC, Baldwin RW. Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody. Nucl Med Commun. 1988;9:931– 941.

Wilbur DS, Hamlin DK, Meyer DL, et al. Streptavidin in antibody pretargeting.3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin. Bioconjug Chem. 2002;13:611–620.

Wilbur DS, Stayton PS, To R, et al. Streptavidin in antibody pretargeting: comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins. Bioconjug Chem. 1998;9:100–107.

Kalofonos HP, Rusckowski M, Siebecker DA, et al. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990;31:1791–1796.

Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991;51:5960–5966

Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al. A pretargeting system for tumor PET imaging and radioimmunotherapy. Front Pharmacol. 2015;6:54.

Divgi C, Carrasquillo JA, Meredith R, et al. Overcoming barriers to radiopharmaceu tical therapy (RPT): an overview from the NRG-NCI working group on dosimetry of radiopharmaceutical therapy. Int J Radiat Oncol Biol Phys. 2021;109:905–912

Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589–608

Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–360

Paganelli G, Chinol M, Grana C, et al. Therapy trials in cancer patients using an improved 3-step pretargeting approach. In: Bergmann H, Kroiss A, Sinzinger H, eds. Radioactive Isotopes in Clinical Medicine and Research: Springer; 1997: 513–517

Axworthy D, Beaumier P, Bottino B, et al. Preclinical optimization of pretargeted radioimmunotherapy components: high efficiency, curative 90Y delivery to mouse tumor xenografts. Tumor Targeting. 1996;2:156.

Murtha A, Weiden P, Knox S, et al. Phase I dose escalation trial of pretargeted radioimmunotherapy (PRIT) with 90yttrium. Proc Am Soc Clin Oncol [abstract]. 1998;17:438.

Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15–29.

Breitz HB, Fisher DR, Goris ML, et al. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999;14:381–395

Press OW, Appelbaum F, Martin P, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336–340.

Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463.

Breitz HB, Weiden PL, Beaumier PL, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTAbiotin. J Nucl Med. 2000;41:131–140.

Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999; 5(suppl):3190s–3198s.

Vuillez J-P, Kraeber-Bodere F, Moro D, et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anticarcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res. 1999;5(suppl):3259s–3267s

Paganelli G, Ferrari M, Ravasi L, et al. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer. Clin Cancer Res. 2007;13:5646s–5651s.

Petronzelli F, Pelliccia A, Anastasi AM, et al. Therapeutic use of avidin is not hampered by antiavidin antibodies in humans. Cancer Biother Radiopharm. 2010;25:563–570.

DeNardo SJ, DeNardo GL, O’Grady LF, et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl. 1988; 3:96–101

DeNardo SJ, DeNardo GL, O’Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers. 1987; 2(1):49–53

Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989; 7(8):1027–1038

Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991; 9(4): 548–564

Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with 131Ianti-B1 (anti-CD20) antibody. N Engl J Med. 1993; 329(7):459–465

Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993; 329(17):1219–1224

Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996; 2(3):457– 470

Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non- Hodgkin’s lymphoma. J Clin Oncol. 1999; 17(12):3793–3803

Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996; 14(7):1974–1981

Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin’s lymphoma: preliminary report. Cancer Biother Radiopharm. 2000; 15(4):347–355

Sgouros G, Squeri S, Ballangrud AM, et al. Patient-specific, 3-dimensional dosimetry in nonHodgkin’s lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor doseresponse. J Nucl Med. 2003; 44(2):260–268

Sharkey RM, Brenner A, Burton J, et al. Radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003; 44(12):2000–2018

Koral KF, Dewaraja Y, Li J, et al. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003; 44(3):457–464

Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab’)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother.2002; 51(1):15–24

Du Y, Honeychurch J, Cragg MS, et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood. 2004; 103(4): 1485–1494

Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2004; 59(5):1274–1287

Kapadia NS, Engles JM, Wahl RL. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med. 2008; 49(4):674–678

Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res. 2008; 14(15):4925–4934

Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium90 ibritumomab tiuxetan. Cancer. 2007; 109(9):1804–1810

Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131Itositumomab therapy for relapsed or refractory indolent non-Hodgkin’s lymphoma. Br J Cancer. 2006; 94(12):1770–1776

Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with nonHodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005; 105(12):4576–4582.

Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007; 25(27):4285–4292

Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin’s lymphoma: a review of the literature. Clin Lymphoma. 2004; 5(3):202–204.

Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352(5):441–449.

Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000; 96(4):1259–1266.

Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005; 23(31):7985–7993.

Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005; 23(24):5696–5704

Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006; 24(25):4143–4149

Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26(32):5156–5164.

Zinzani PL, Tani M, Fanti S, et al. A Phase II trial of CHOP chemotherapy followed by yttrium90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. 2008; 19(4):769–773

Russo AL, Chen YH, Martin NE, et al. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. Int J Radiat Oncol Biol Phys 2013; 86:121.

Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10:7792.

Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336.

Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429.

Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 2007; 22:684.

Jurcic JG, Scheinberg DA. Radioimmunotherapy of hematological cancer: problems and progress. Clin Cancer Res. 1995; 1(12):1439–1446

McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med. 1998; 25(9):1341–1351

Nikula TK, McDevitt MR, Finn RD, et al. α-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med. 1999; 40(1):166–176

Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999; 40(11):1935–1946

Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia.Blood. 2002; 100(4):1233–1239.

Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003; 63(16):5084–5090

Yao Z, Zhang M, Garmestani K, et al. Pretargeted α emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane-N, N’, N’, N’-tetraacetic acid-biotin. Clin Cancer Res. 2004; 10(9): 3137–3146

Jaggi JS, Seshan SV, McDevitt MR, et al. Renal tubulointerstitial changes after internal irradiation with α-particle-emitting actinium daughters. J Am Soc Nephrol. 2005; 16(9):2677–2689

Jaggi JS, Seshan SV, McDevitt MR, et al. Mitigation of radiation nephropathy after internal αparticle irradiation of kidneys. Int J Radiat Oncol Biol Phys. 2006; 64(5):1503–1512

Song H, Hobbs RF, Vajravelu R, et al. Radioimmunotherapy of breast cancer metastases with αparticle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009; 69(23):8941–8948.

Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 2006; 47:247.

Chatal JF, Campion L, Kraeber-Bodéré F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anticarcinoembryonic- antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24:1705.

Iten F, Müller B, Schindler C, et al. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007; 13:6696.

Grossrubatscher E, Fanciulli G, Pes L, et al. Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. J Clin Med 2020;9.

Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131- labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a Phase I trial. J Clin Oncol.1997; 15(4):1518-1528

Wong JYC, Chu DZ, Yamauchi DM, et al. A Phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 2000; 6(10):3855–3863

Tempero M, Leichner P, Baranowska-Kortylewicz J, et al. High-dose therapy with 90yttriumlabeled monoclonal antibody CC49: a Phase I trial. Clin Cancer Res. 2000; 6(8):3095-3102

Wong JY, Shibata S, Williams LE, et al. A Phase I trial of 90Y-anti-carcinoembryonic antigenchimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003; 9(16 Pt 1):5842–5852